52243 AH-001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia

September 2024 in “ Journal of the American Academy of Dermatology ”

Chih-Chang Chou, Peng Cheng, Hsin‐Hung Chen, Kuan Hung Chen, Ching‐Tang Wu, Jing Jiao, Chien‐Tsong Lin

AH-001 androgen receptor degrader androgenetic alopecia AR protein VCaP cells DHT hair loss murine model minoxidil finasteride androgen receptor dihydrotestosterone mouse model Rogaine Propecia

From the encyclopedia

Minoxidil →

An essential vasodilator with some anti-androgenic effects

Finasteride →

Frontline, gold standard treatment for combatting androgenic alopecia

Studysummary In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment. Our plain-language summary of this paper — not a Tressless recommendation.

The study introduces AH-001, a novel androgen receptor degrader, as a promising treatment for androgenetic alopecia (AGA). AH-001 effectively targets and degrades AR protein, showing potent efficacy in VCaP cells and reversing hair loss in a murine AGA model with minimal systemic exposure. Importantly, AH-001 did not cause serious adverse effects even at high doses in rats and showed no local skin irritation, addressing common side effects of current AGA treatments like minoxidil and finasteride. This suggests AH-001 has significant therapeutic potential for managing AGA.

View this study on jaad.org →

Discuss this study in the Community →